NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 03 04:00PM ET
6.75
Dollar change
+0.17
Percentage change
2.58
%
Index- P/E- EPS (ttm)-29.44 Insider Own- Shs Outstand0.97M Perf Week3.37%
Market Cap6.55M Forward P/E- EPS next Y- Insider Trans- Shs Float- Perf Month40.92%
Enterprise Value4.74M PEG- EPS next Q- Inst Own11.53% Short Float- Perf Quarter68.75%
Income-18.73M P/S4.31 EPS this Y- Inst Trans12.63% Short Ratio0.23 Perf Half Y-56.45%
Sales1.52M P/B- EPS next Y- ROA-135.08% Short Interest0.20M Perf YTD-23.73%
Book/sh-2.44 P/C3.45 EPS next 5Y- ROE-3028.18% 52W High79.00 -91.46% Perf Year-37.73%
Cash/sh1.96 P/FCF- EPS past 3/5Y-7.62% 11.47% ROIC- 52W Low2.86 136.01% Perf 3Y-97.11%
Dividend Est.- EV/EBITDA- Sales past 3/5Y-48.89% - Gross Margin- Volatility9.40% 15.02% Perf 5Y-95.63%
Dividend TTM- EV/Sales3.12 EPS Y/Y TTM-32.63% Oper. Margin-1264.44% ATR (14)0.92 Perf 10Y-99.39%
Dividend Ex-Date- Quick Ratio0.24 Sales Y/Y TTM- Profit Margin-1232.83% RSI (14)53.24 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio0.21 EPS Q/Q32.30% SMA20-7.02% Beta2.62 Target Price15.00
Payout- Debt/Eq- Sales Q/Q- SMA5032.34% Rel Volume0.34 Prev Close6.58
Employees- LT Debt/Eq- Earnings- SMA200-42.18% Avg Volume867.69K Price6.75
IPOJan 06, 1999 Option/ShortNo / Yes EPS/Sales Surpr.- - Trades Volume294,323 Change2.58%
Date Action Analyst Rating Change Price Target Change
Feb-06-25Initiated Maxim Group Buy $3
Oct-14-21Initiated Maxim Group Buy $18
Jan-05-21Initiated H.C. Wainwright Buy $17
Jun-11-25 08:00AM
Jun-05-25 08:00AM
May-15-25 08:00AM
Mar-31-25 07:30AM
Feb-20-25 08:46AM
07:29AM Loading…
Jan-31-25 07:29AM
Jan-30-25 07:30AM
Jan-27-25 08:00AM
Jan-14-25 04:00PM
Jan-11-25 10:05AM
Jan-10-25 09:58AM
Dec-31-24 12:34PM
08:00AM
Dec-11-24 08:00AM
Nov-04-24 07:30AM
07:27AM Loading…
Oct-16-24 07:27AM
Oct-15-24 07:32AM
Oct-02-24 08:45AM
Sep-23-24 08:30AM
Sep-12-24 07:30AM
Jul-31-24 09:53AM
07:00AM
Jul-25-24 06:10AM
Jul-12-24 11:24AM
10:08AM
07:41AM
Jul-11-24 01:26PM
01:01PM
12:51PM
12:31PM
07:29AM Loading…
07:29AM
06:32AM
Jul-10-24 12:42PM
12:08PM
11:57AM
07:30AM
Jun-27-24 08:15AM
May-23-24 02:41PM
May-21-24 07:39AM
May-02-24 04:22AM
May-01-24 08:45AM
Mar-24-24 07:55AM
Mar-21-24 08:52AM
Mar-13-24 08:00AM
Feb-21-24 07:30AM
Jan-18-24 07:30AM
Dec-05-23 06:02PM
Dec-01-23 08:00AM
Nov-29-23 07:01AM
Nov-21-23 07:30AM
Nov-20-23 04:30PM
Nov-15-23 08:30AM
Nov-10-23 07:01AM
Nov-01-23 07:01AM
Oct-23-23 07:01AM
Oct-11-23 07:01AM
Oct-05-23 07:01AM
Sep-29-23 07:01AM
Jul-06-23 07:00AM
Jun-08-23 07:00AM
May-25-23 07:01AM
Apr-14-23 07:01AM
Apr-04-23 07:00AM
Jan-25-23 03:03PM
Jan-18-23 11:50AM
Jan-16-23 07:01AM
Dec-19-22 09:00PM
Dec-15-22 07:01AM
Dec-12-22 07:01AM
Dec-01-22 07:01AM
Nov-28-22 04:50PM
Nov-09-22 07:00AM
Nov-02-22 07:10AM
Oct-27-22 10:48AM
07:00AM
Oct-06-22 08:00AM
Sep-26-22 09:55AM
Sep-09-22 08:00AM
Sep-08-22 06:00PM
Sep-07-22 10:35AM
Aug-11-22 09:55AM
Aug-05-22 10:00AM
08:40AM
Aug-01-22 07:00AM
Jul-17-22 06:28PM
Jul-12-22 08:15AM
Jul-06-22 07:00AM
Jun-17-22 08:00AM
Jun-13-22 07:00AM
Jun-08-22 08:49PM
Jun-07-22 07:00AM
Jun-03-22 07:00AM
May-31-22 07:00AM
May-26-22 07:50AM
May-23-22 08:30AM
May-17-22 08:00AM
May-16-22 09:12PM
Apr-29-22 11:00AM
Apr-08-22 08:30AM
08:00AM
Kazia Therapeutics Ltd. is an oncology-focused biotechnology company, which engages in the business of pharmaceutical drug development. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.